This study is looking at how your primary language might affect the treatment you receive for inflammatory bowel disease (IBD) and how well that treatment works. Researchers want to understand if using a translator or having different cultural backgrounds impacts the choices made about IBD medications and your health outcomes. This is an observational study, meaning you won't receive any new interventions or treatments as part of the study. Instead, researchers will gather information about your current treatment and health. You can join if you are 18 or older, have a confirmed IBD diagnosis, and are managed at an outpatient clinic within the Yale New Haven Hospital or University of Texas at Austin Hospital systems. The main goal is to see how your language affects the use of advanced IBD therapies at the start of the study.

Study design

This is an observational study with a planned enrollment of 206 participants. It is not testing a new drug or intervention.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, current use of advanced therapy, is measured at baseline (the start of the study).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.